Efficacy and Tolerability of Paliperidone Extended-release in the Treatment of First-episode Psychosis: An Eight-week, Open-label, Multicenter Trial
| العنوان: | Efficacy and Tolerability of Paliperidone Extended-release in the Treatment of First-episode Psychosis: An Eight-week, Open-label, Multicenter Trial |
|---|---|
| المؤلفون: | Myung Hun Jung, Bon-Hoon Koo, Seung-Jae Lee, Bong Ju Lee, Sung-Wan Kim, Sang Woo Hahn, Beomwoo Nam, Seung Hwan Lee, Jong-Hoon Kim, Sang-Hyuk Lee, Young-Chul Chung, Nam-In Kang |
| المصدر: | Clinical Psychopharmacology and Neuroscience |
| بيانات النشر: | Korean College of Neuropsychopharmacology, 2016. |
| سنة النشر: | 2016 |
| مصطلحات موضوعية: | medicine.medical_specialty, Efficacy, Global Assessment of Functioning, Akathisia, 03 medical and health sciences, Behavioral Neuroscience, 0302 clinical medicine, Internal medicine, Multicenter trial, medicine, Pharmacology (medical), Paliperidone, Scale for the Assessment of Negative Symptoms, Paliperidone extended-release, Positive and Negative Syndrome Scale, business.industry, First-episode psychosis, Tolerability, 030227 psychiatry, Barnes Akathisia Scale, Psychiatry and Mental health, Original Article, medicine.symptom, business, 030217 neurology & neurosurgery, medicine.drug |
| الوصف: | Objective We investigated the efficacy and tolerability of paliperidone extended-release (ER) tablets in patients with first-episode psychosis (n=75). Methods This was an 8-week, open-label, multicenter trial. The primary outcome variable was scores on the Positive and Negative Syndrome Scale (PANSS); secondary measures included the Scale for the Assessment of Negative Symptoms (SANS), the Cognitive Assessment Interview (CAI), and the Global Assessment of Functioning (GAF). To assess safety, we measured drug-related adverse events, weight, lipid-related variables, and prolactin and administered the Simpson-Angus Rating Scale (SARS), the Abnormal Involuntary Movement Scale (AIMS), the Barnes Akathisia Scale (BAS), the Arizona Sexual Experiences Scale (ASEX), and the Udvalg for Kliniske Undersogelser side effect rating scale (UKU). Results The administration of paliperidone ER resulted in significant improvement in the PANSS, SANS, CAI, and GAF scores (p＜0.001) over time. This improvement was evident as early as 1 week. The most frequent adverse events were akathisia, somnolence, anxiety, and sedation, which were well tolerated. Modest increases in weight and lipid profiles were also noted. Prolactin levels were substantially increased at the endpoint in both male and female patients. Conclusion These results indicate that paliperidone ER is effective and is characterized by good tolerability in the treatment of positive and negative symptoms and cognitive functioning in first-episode psychosis. |
| تدمد: | 2093-4327 1738-1088 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab66db27733d5c4dbfeafacb522a321aTest https://doi.org/10.9758/cpn.2016.14.3.261Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....ab66db27733d5c4dbfeafacb522a321a |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20934327 17381088 |
|---|